Surgical vs TranscatheterWednesday, May 27, 2026

The Legacy of the First Valve: Outcomes of Redo Surgical Aortic Valve Replacement After Prior Transcatheter Versus Prior Surgical Aortic Valve Replacement-A Narrative Review.

1 min read·By E. Nolan Beckett, MD·Source: Journal of clinical medicine

Key Numbers

144.6% annually

17% in TAVR

9% in SAVR

11.3% vs

From The Valve Wire

Second, an analysis of patients aged 50-70 found mechanical aortic prostheses outperformed bioprostheses for long-term survival , with 19-mm bioprostheses showing the worst outcomes and severe PPM driving lowest survival.

The Cedars-Sinai NCT07605715 randomized trial of transcatheter vs surgical degenerative MR repair just began recruiting (N=60) — small, but a symbolically important head-to-head in primary MR where surgery currently dominates both guidelines.

The narrative arc: every transcatheter advance carries a downstream reintervention cost when applied to patients with 15+ years of life expectancy.

Editor’s take pending for this article; this is the section commentary excerpt.

Source Abstract

Transcatheter Aortic Valve Replacement (TAVR) has transformed aortic stenosis management across the full risk spectrum, but expansion into younger populations makes valve failure and reintervention central to lifetime planning. There are two pathways to follow when TAVR fails: redo transcatheter implantation and surgical explantation with surgical aortic valve replacement (SAVR), termed TAVR-SAVR. This narrative review synthesizes evidence from four studies (35,677 patients, 2011-2024) examining the association between prior valve type and redo SAVR outcomes versus redo SAVR after prior surgical prosthesis (SAVR-SAVR). TAVR-SAVR volume grew at up to 144.6% annually, projected to surpass SAVR-SAVR by approximately 2029 based on linear extrapolation from limited registry and single-center data. Operative mortality was 12.3-17% in TAVR-SAVR versus 1.1-9% in SAVR-SAVR, persisting after propensity matching in both comparative studies (11.3% vs. 6.7%, OR 1.7; and 12.0% vs. 1.1%, OR 12.5). Observed-to-expected mortality ratios exceeded 1.0 across all risk strata, including low-risk patients (O/E up to 5.48), while SAVR-SAVR demonstrated a remarkably low ratio of 0.22-0.33. Renal failure, failure to rescue, and prolonged ventilation were significantly higher following TAVR-SAVR; stroke and pacemaker rates were comparable. Paradoxically, shorter bypass and cross-clamp times in TAVR-SAVR despite worse outcomes are consistent with cumulative organ injury, rather than operative complexity, as a predominant contributor to excess mortality, though this mechanistic explanation remains hypothetical. STS risk models, developed for standard surgical populations, showed limited applicability in this population, with observed mortality consistently exceeding predicted values. These findings raise important considerations regarding TAVR-first strategies in operable patients aged 65-80 years, although causality cannot be established from observational data alone. In the era of expanding TAVR indications, the legacy of the first valve cannot be ignored.

Authors: Magouliotis DE, Sicouri S, Androutsopoulou V, Xanthopoulos A, Brecher V et al.

Read the Original

Full article at Journal of clinical medicine

Open at Journal of clinical medicine →

The Valve Wire summarizes; we link out to primary sources for verification.